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Abstract We aimed to study the potential influence of the
variability in the assessment of echocardiographically
measured left ventricular ejection fraction (LVEF) on
indications for the implantation of internal cardioverter
defibrillator and/or cardiac resynchronization devices in
heart failure patients. TIME-CHF was a multicenter trial
comparing NT-BNP versus symptom-guided therapy in
patients aged C60 years. Patients had their LVEF assessed
at the recruiting centre using visual assessment, the area-
length or biplane Simpson’s method. Echocardiographic
data were transferred to the study core-lab for re-assess-
ment. Re-assessment in the core-lab was done with biplane
Simpson’s method, and included an appraisal of image
quality. 413 patients had the LVEF analyzed at the
recruiting centre and at the core lab. Image quality was
optimal in 191 and suboptimal in 222. Overall, the corre-
lation between LVEF at the recruiting centres and at the
core-lab was good, independent of image quality (R2 =
0.62). However, when a LVEF B30 % or C30 % was used
as a cut-off, about 20 % of all patients would have been
re-assigned to having either a LVEF above or below the cut-
off, this proportion was not significantly influenced by
image quality. We conclude that correlation between LVEF
assessed by different centres based on the same ultrasound
data is good, regardless of image quality. However, one fifth
of patients would have been re-assigned to a different cat-
egory when using the clinically important cut-off of 30 %.
Keywords Device therapy  Left ventricular ejection
fraction  Variability  Clinical decision-making 
Heart failure
Introduction
Large trials have shown a survival benefit after the
implantation of an internal cardioverter defibrillator (ICD)
or cardiac resynchronization therapy (CRT) in patients
with a severely reduced left ventricular ejection fraction
(LVEF) [1–3]. One of the selection criteria in these trials
was the reduction of LVEF below a predefined threshold,
and transthoracic echocardiography was one of the accep-
ted imaging methods for assessing LVEF. Similarly,
guidelines for the treatment of heart failure advocate the
initiation of angiotensin converting enzyme inhibitor and
b-blocker therapy using predefined LVEF cut-offs [4, 5].
Therefore, important treatment decisions in this patient
group with a high mortality are currently based on the
measurement of LVEF by transthoracic echocardiography,
both in large randomized clinical trials but also in daily
clinical practice.
However, although validated as a prognostic indicator in
cardiac diseases [6, 7] and successfully used in clinical
trials to detect even small changes in ejection fraction in
large patient groups [8–10], the measurement of LVEF by
2-dimensional transthoracic echocardiography is fraught
with a considerable interobserver variability. 3-dimen-
sional echocardiography and left ventricular opacification
with 2nd generation contrast media have been shown to
improve the accuracy of the measurement of LVEF.
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However, despite recommendations by recent guidelines
[11], these newer methods are not yet widely used in daily
clinical practice. Therefore, assessment of LVEF for the
selection of therapies like ICD or CRT is most often per-
formed by 2-dimensional echocardiography. Given the
inherent risks of ICD and CRT implantation and the
associated costs, the best possible accuracy in measurement
of LVEF is warranted. In this study we investigated the
variability in the assessment of LVEF with 2-dimensional
echocardiography, and the potential impact of this vari-
ability on treatment decisions. We also aimed to relate
variability in the assessment of LVEF and its effect on
treatment decisions to the image quality of the echocar-
diographic exams and to investigate other potential pre-
dictors of variability. We performed this analysis in a large,
real world heart failure population.
Methods
Study population
TIME-CHF was a multicenter trial comparing an intensi-
fied, BNP-guided treatment strategy with a conventional
medical treatment strategy in patients aged 60 years or
more with heart failure irrespective of LVEF. The design
of the TIME-CHF trial has been described elsewhere in
detail [12, 13]. Briefly, patients with dyspnea (New York
Heart Association class II or higher on current therapy), a
history of hospitalization for heart failure within the past
year, and an elevated N-terminal BNP level ([400 pg/ml in
patients \75 years, and [800 pg/ml in patients C75 years
of age) were recruited in 15 tertiary and secondary hospital
centers in Switzerland and Germany. Exclusion criteria
were dyspnea not mainly due to heart failure, valvular heart
disease requiring surgery, acute coronary syndrome within
ten days before study inclusion, angina pectoris [CCS 2,
revascularization within the month before study inclusion,
body mass index[35, serum creatinine[2.49 mg/dL, a life
expectancy of less than 3 years due to non-cardiovascular
causes, inability to give informed consent, follow-up
impossible, or participation in another study. All patients
gave written informed consent. The study was approved by
the local ethics committee of each participating center.
Overall, 622 patients were included in the TIME-CHF trial.
Study protocol
Upon inclusion in the study, patients had transthoracic
echocardiography performed at the recruiting center by a
board certified cardiologist trained in echocardiography.
Standard clinical ultrasound equipment was used for
acquisition of cine loops documenting left ventricular
function from parasternal and apical acoustic windows
with broadband transducers operating in harmonic imaging
mode. The LVEF was determined by the treating cardiol-
ogist at the recruiting hospitals either by visual assessment
or using tracking of the endothelial border and accepted
mathematical models (Biplane Simpson’s method or area
length method). The echocardiographic studies were stored
digitally and transferred to the echocardiography core
laboratory at the University Hospital of Basel. Clinical data
were derived from the central database of TIME-CHF. Of
the 622 patients, 413 (66.4 %) had a complete set of
echocardiographic images transmitted to the core labora-
tory, and comprise the patient group for the present study.
At the core laboratory, the LVEF was re-assessed by two
readers (SYM and KG) blinded to results from the
recruiting center. The LVEF was determined from pla-
nimetry of cineloops of the apical 4- and 2-chamber win-
dows at end-diastole and end-systole using biplane
Simpson’s method according to the recommendations of
the American Society of Echocardiography [14], leaving
the papillary muscles and trabeculations within the cavity.
The interobserver variability for these two readers was
determined in a randomly selected subset of 30 patients for
each of the two reader by re-assessment by a third reader
(BAK) blinded to the LVEF values. Interobserver vari-
ability was 4.8 ± 3.8 % for SYM and 4.5 ± 3.3 % for KG.
Regional wall motion was rated for the anterior, inferior,
septal lateral, and apical myocardial segments by the same
readers on a 5-point scale (1 = normal, 2 = mild hypo-
kinesia, 2 = severe hypokinesia, 3 = akinesia, 4 = dys-
kinesia). The presence of a 2 or more points difference in
wall motion score between adjacent segments was con-
sidered to represent a regional wall motion defect. Image
quality was assessed independently by a third investigator
(BAK) without knowledge of the LVEF values or clinical
details. Image quality was rated as bad when only 50–60 %
of the endocardial border could be well visualized in any of
the standard apical image planes, as fair when 60–74 % of
the endocardial border could be discerned, and as good
when 75–100 % of the endocardial border was visible [15].
For the present analysis, subjects were classified into a
group with optimal image quality (those classified as
having good image quality) and suboptimal image quality
(those having bad or fair image quality).
Statistics
Statistical analyses were performed using SPSS Version
16.0 (SPSS Inc.). Variability was defined as the absolute
difference between the two LVEF measurements. Contin-
uous variables were compared between subgroups using a t
test or Mann–Whitney test, as appropriate. Categorical
variables were compared using Fisher’s exact test.
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Correlations were assessed using linear regression analysis,
followed by Bland–Altman analysis for assessing the
agreement between the two LVEFs. Multivariate linear
regression was used for assessment of potential predictors




The Table 1 shows basic parameters and clinical parame-
ters that may be relevant to echocardiographic image
quality. Of the 413 patients included, 191 (46 %) had a
good image quality, while 157 (38 %) had a fair image
quality and 65 (15.7 %) had a bad image quality. Thus, 191
(46 %) of the patients were classified as having an optimal
image quality, and 222 (54 %) as having a suboptimal
image quality. Patients in the group with suboptimal image
quality had a higher body mass index. No difference was
seen in the presence of systolic dysfunction, coronary
artery disease, cardiomyopathy or chronic obstructive lung
disease. The LVEFs assessed at the core laboratory ranged
from 15 to 75 %, the ones assessed at the recruiting centers
from 8 to 77 %. 171 (41 %) of the patients had a LVEF that
was assessed as B35 % at the core lab. Two hundred nine
patients from the original TIME-CHF study population
were not included in the present study, either because of
the unavailability of digital image sets from two recruiting
centers, or because of incomplete imaging datasets.
Regarding the basic and clinical parameters, these 209
patients differed from the included patients in that they
were younger (75.8 ± 7.6 vs. 77.5 ± 7.5 years, p = 0.007),
and in that they had a lower proportion of coronary artery
disease (56.9 vs 68.0 %, p = 0.008), but there were no
differences regarding BMI, gender, systolic dysfunction,
cardiomyopathy, COPD or LVEF as reported by the
recruiting center.
Variability in determination of LVEF
For the whole patient population, there was a highly sig-
nificant correlation between the two measurements of
LVEF with an R2 of 0.62. However, Bland–Altman anal-
ysis showed a wide 95 % confidence interval of the dif-
ferences ranging from -17.4 to ?17.8 % despite a small
overall bias of 0.2 % (Fig. 1), and the variability between
the recruiting center and the core lab was 14.1 ± 10.9 %.
When the whole patient population was separated into
patients with optimal image quality and patients with
suboptimal image quality, the correlation for the two
measurements remained highly significant for both sub-
populations with an R2 of 0.65 in the subpopulation with
optimal image quality, and an R2 of 0.59 in the subpopu-
lation with suboptimal image quality. Bland–Altman
analysis again showed small biases for both subpopulations
(1.0 % in the subpopulation with good image quality, and
1.3 % in the subpopulation with suboptimal image quality).
However, the 95 % confidence intervals were large for both
subgroups, though somewhat smaller in the subpopulation
with optimal image quality (95 % CI -16.3 to ?18.4 % in
the subpopulation with optimal image quality, 95 % CI
-16.5 to ?19.1 % in the subpopulation with suboptimal
image quality) (Fig. 2). Variability between LVEF
assessment in the recruiting centers and measurements at
the core lab was 14.5 ± 10.3 % for the subpopulation with
optimal image quality, and 13.8 ± 10.3 % for the subgroup
with suboptimal image quality (p = 0.23 for the difference
between the 2 subgroups).
Overall, the median of the difference between the two
LVEF measurements was 5.2 % (IQR 2.5–9.6). Only a
Table 1 Clinical characteristics in the overall study patients and in patients with suboptimal versus good image quality
Overall Echo quality p
Optimal Suboptimal
n = 413 n = 191 n = 222
Age (years ± SD) 77.5 ± 7.5 78.0 ± 7.3 77.1 ± 7.7 0.22
BMI (kg/m2 ± SD) 25.4 ± 4.4 24.5 ± 4.3 26.5 ± 4.4 B0.0001
Male (%) 240 (58.0) 111 (58.1) 129 (58.1) 1.0
Systolic dysfunction (%)a 329 (79.7) 147 (77.0) 182 (82) 0.22
CAD 281 (68.0) 126 (66.0) 1455 (69.8) 0.46
RWMD 163 (39.5) 77 (40.3) 85 (38.3) 0.78
Cardiomyopathy 61 (14.8) 28 (14.7) 33 (19.9) 0.87
COPD 83 (20.1) 37 (19.4) 46 (20.7) 0.80
BMI Body mass index, CAD coronary artery disease, RWMD regional wall motion defect, COPD chronic obstructive pulmonary disease
a Systolic dysfunction defined as LVEF B 45 %
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limited number of significant predictors for this difference
could be identified in univariate analysis. Thus, it was
smaller in male (median [IQR] 4.4 % [2.4–8.6 %]) com-
pared to female (6.6 [2.6–11.1], p = 0.004). Furthermore, a
larger difference was correlated with higher heart rate (r =
0.12, p = 0.01), shorter QRS duration (r = -0.11, p =
0.03), and smaller LV ventricles (end-diastolic volume of
LV [LVEDV] r = -0.17, p = 0.001). Other predictors
were not significantly correlated with the difference
between the two measurements, particularly body mass
index, presence of COPD, cause of heart failure, and the
centre where initial assessment was done. In multivariate
analysis, the only independent predictor was the LVEDV.
163 patients (39 %) in the whole study population had
regional wall motion defects. These patients showed a
highly significant correlation between the two measure-
ments of LVEF (R2 of 0.38, p B 0.0001). Again, Bland–
Altman analysis showed a wide 95 % confidence interval
of the differences ranging from -15.5 to ±17.1 % with an
overall bias of 0.8 %.
Potential influence of the reliability in determination of
LVEF on clinical decision-making
Discrete LVEF thresholds are used for important clinical
decisions, and therefore we examined what potential
influence the intercenter reliability in the determination of
LVEF could have on situating an individual patient above
or below commonly used threshold values (Fig. 3). For a


























































95% CI -17.4 to 17.8
Fig. 1 a Correlation between LVEF measured at the recruiting center
and biplane LVEF measured at the core laboratory by linear
regression analysis (solid line) for the whole patient group.
b Bland–Altmann plot of the same data, dashed lines specify mean
difference of the measurements, dotted lines the corresponding 95 %
confidence interval (CI)



























































y = 0.68x + 11.9
R2 = 0.59
p<0.0001
















CFig. 2 a Correlation between
LVEF measured at the
recruiting center and biplane
LVEF measured at the core
laboratory by linear regression
analysis (solid line) for the
patients with optimal image
quality. b Bland–Altmann plot
of the same data, dashed lines
specify mean difference of the
measurements, dotted lines the
corresponding 95 % confidence
interval (CI). c Correlation
between LVEF measured at the
recruiting center and biplane
LVEF measured at the core
laboratory for the patients with
suboptimal image quality.
d Bland–Altmann plot of the
same data
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threshold of an LVEF of 30 %, in the whole patient pop-
ulation, 21.1 % of all patients changed from either B30 to
[30 % or vice versa. For the same threshold, the per-
centages of re-assignment were 23.0 % for patients with
optimal image quality and 19.4 % for patients with sub-
optimal image quality (p for the difference in proportions
0.40). For a threshold of an LVEF of B35 %, 16.9 % were
re-assigned in the whole patient population. For patients
with optimal image quality the percentage of re-assignment
was 16.2 %, for patients with suboptimal image quality
17.6 % (p for the difference in proportions 0.79). For a
threshold of an LVEF of B40 %, 13.6 % were re-assigned
in the whole patient population. For patients with optimal
image quality the percentage of re-assignment was 13.1 %,
for patients with suboptimal image quality 14.1 % (p for
the difference in proportions 0.39). For the threshold of a
normal LVEF of C55 %, 6.3 % were re-assigned in the
whole patient population, 5.9 % in the subpopulation with
optimal image quality, and 6.8 % in the subpopulation with
suboptimal image quality (p for the difference in propor-
tions 0.69).
Discussion
Our study shows a high variability in the evaluation of
LVEF in a large study of patients with heart failure with
both reduced ejection fraction and normal ejection fraction.
This high variability resulted despite the fact that the same
image material was used for analysis at the recruiting
center and at the echocardiography core laboratory. Using
commonly accepted cut-offs for the implantation of ICD or
CRT, 15–20 % of all patients were re-classified as having a
LVEF above or below the cut-offs when the images were
re-assessed. Neither the variability in LVEF assessment
between hospital centers nor the percentages of patients re-
classified depended significantly on the quality of the
acquired ultrasound images. The only independent pre-
dictor of a high variability in LVEF measurements was a
smaller left ventricle.
Interobserver reliability
The numeric assessment of LVEF is the single most
important measurement in cardiology with a profound
influence on diagnosis and management of patients. Hence,
it is of utmost importance that this measurement is reliable
and reproducible. While other imaging modalities in use in
current cardiology practice (angiography, SPECT, MRI, CT,
RNA) can provide measurements of LVEF, two-dimen-
sional echocardiography is by far the most commonly
employed method. Two-dimensional echocardiography for
the measurement of LVEF relies on either a visual assess-
ment of ventricular function, or on tracings of the endocar-
dial borders and calculation of LVEF using geometric
models (Simpson’s biplane analysis, area length method). In
comparison to other imaging modalities, two-dimensional
echocardiography has the disadvantages of (1) dependence
on unequivocal endocardial border delineation, which is not
uniformly achieved in all echocardiographic images, and (2)
reliance on geometric assumptions in the case of LVEF
measurement by Simpson’s biplane method or area length
method. The accuracy of these echocardiographic methods
for the assessment of LVEF in comparison with SPECT,
MRI and CT has been studied extensively [16–18] and
overall correlations have been shown to be good. Thus,
2-dimensional echocardiography is a valuable tool for
assessing treatment effects in therapeutic trials. However,
there has been concern regarding interstudy, interobserver
and intraobserver variability of 2-dimensional echocardio-
graphic measurements of LVEF, especially with regards to
the serial assessment of changes in ejection fraction, and
inclusion or exclusion of subjects into studies where LVEF
thresholds are used as inclusion criteria. By the design of the
present study, the LVEF assessment at the recruiting hospital
was done either by visual assessment, Simpson’s biplane or
area length assessment, and thus the 95 % confidence
interval of the differences do not represent a strict mea-
surement of interobserver variability. Nevertheless, the
variabilities in our study correspond to previously published
values of interobserver variability [19, 20], while others have
published lower values [21–23]. An important difference























A B CFig. 3 Correlation of LVEF
measured at the recruiting
center and biplane LVEF
measured at the core laboratory
for a the whole patient group,
b patients with optimal image
quality, and c patients with
suboptimal image quality.
Those datapoints for which a
reclassification from B30 to
[30 % occurred are shaded in
grey
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between the cited studies and our data is that we investigated
the variability between hospital centers in the assessment of
LVEF in a large, real world clinical heart failure trial, while
the cited studies were conducted specifically to assess the
accuracy and interobserver variability of different imaging
methods for the assessment of LVEF in a lower number of
subjects. Thus, our study can be assumed to more reliably
indicate the variability of LVEF measurements as performed
in routine cardiology practice. The variability in the
assessment of LVEF in our study was largely independent of
the quality of the echocardiographic images. Others have
described a better agreement for echocardiography with
other imaging techniques in those patients with better image
quality [15]. In our study, 53.8 % of patients were deemed to
have a suboptimal image quality, which seems to be a rela-
tively high number. The large percentage of patients with
suboptimal image quality may be due to the fact that a real
world population was examined. More importantly, the
assessment of image quality was performed at the core lab to
assess its effect on the reliability in measurement of LVEF
and reclassification above or below a threshold. To our own
surprise, image quality did not have a significant impact on
variability, and thus image quality did not impact the main
study results. However, our dataset is likely to more closely
reflect a real-world situation than data from dedicated
imaging studies. Importantly, only a very limited number of
factors potentially influencing the variability could be in-
dentified in this study. Of these variables, only the enddia-
stolic volume of the LV was an independent, albeit very
limited predictor.
Reclassification
A large proportion of patients were reclassified below or
above clinically relevant thresholds when the echocardio-
graphic images were reassessed. These proportions were
similar for cut-offs of 30, 35, and 40 %, all of which are
important for clinical decision-making. The proportion of
reclassification was lower regarding the cut-off of a normal
LVEF, but this seems to be due to the smaller number of
patients included in this study with normal LVEF. Previous
information on reclassification is very limited. Thus,
Chuang et al. compared 2 dimensional echocardiography
with CMR with regards to classification of LVEF as nor-
mal (C55 %), depressed (LVEF[35 to 55 %) or severely
depressed (B35 %) in a total of 35 patients, and found that
up to 44 % of patients were classified differently by
echocardiography. Similarly, Ray et al. [24] compared 2D
echocardiography to radionuclide ventriculography in 70
patients, and found that 40 % of patients would have been
classified differently depending on the imaging test used.
Given the far-reaching consequences of placing individuals
above or below a certain LVEF threshold, especially with
regards to device implantation, the high rate of reclassifi-
cation in our study is worrying, as it may lead to higher
numbers needed to treat both in clinical trials, but also in
real world patients. Contrast-enhanced echocardiography
and three-dimensional echocardiography have been shown
to improve both the accuracy of LVEF determinations
when compared to reference methods, as well as to reduce
interobserver variability [20, 25]. However, the benefit of
these new techniques with regards to misclassification of
patients above or below LVEF cutoffs remains to be
determined. In addition, our data indicate that studies,
especially single center studies, that are specifically
designed to test the accuracy and reproducibility of imag-
ing methods, tend to underestimate the measurement var-
iability observed in clinical practice.
Study limitations
LVEF assessment at the recruiting hospital centers was
done according to the preferences of the investigators with
either visual assessment or biplane Simpson’s method,
whereas in the echocardiographic core laboratory all
LVEFs were measured using biplane Simpson’s method.
Thus, we do not report a true interobserver variability. This
may have increased the variability we report in this study.
Also, the fact that the readers at the core lab, but not the
cardiologist at the recruiting center were blinded for the
clinical characteristics of the patient might have further
increased variability. However, differences in the meth-
odology used for LVEF assessment are the reality in
clinical practice, and thus our data closely reflect the true
variability of LVEF measurements with two-dimensional
echocardiography in daily clinical practice.
Conclusions
Conventional 2D echocardiographic assessment of LVEF
carries with it a considerable variability. This variability is
not dependent on overall image quality and identification
of factors potentially influencing this variability is very
limited. A significant proportion of patients (i.e. 15–20 %)
would have been re-assigned to a different LVEF category
upon reassessment of the echocardiographic images. Thus,
the reported variability in LVEF assessment appears to
have an important potential impact on clinical decision-
making, especially on the indication for the implantation of
an ICD or CRT device. Whether the standard use of
biplane Simpson’s method for LVEF calculations or other
imaging modalities would reduce variability of LVEF
assessment and its impact on clinical decision-making, and,
importantly, would also be applicable in clinical practice
remains to be determined.
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